| Business Summary | | AeroGen,
Inc.
specializes
in
the
development,
manufacture
and
commercialization
of
products
for
the
controlled
delivery
of
drugs
to
the
lungs.
The
Company's
core
technology
consists
of
a
proprietary
aerosol
generator.
The
Company
is
developing
products
in
collaboration
with
pharmaceutical
and
biotechnology
companies
for
both
respiratory
therapy
and
for
the
delivery
of
drugs
through
the
lungs
to
the
bloodstream.
The
Company
is
in
the
development
stage
and
has
devoted
substantially
all
of
its
efforts
to
the
development
of
products.
The
Company
intends
to
create
and
market
a
respiratory
disease
product
portfolio
consisting
of
its
nebulizers
and
AeroDose
inhalers.
AeroGen
will
initially
target
the
AeroDose
inhalers
for
delivery
of
drugs
that
are
currently
administered
by
nebulizers
to
the
lungs
of
the
young
and
the
elderly.
Its
initial
target
diseases
are
pediatric
asthma,
chronic
obstructive
pulmonary
disease
and
cystic
fibrosis. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | AeroGen
specializes
in
the
development,
manufacture
and
commercialization
of
products
for
the
controlled
delivery
of
drugs
to
the
lungs.
For
the
six
months
ended
6/30/01,
revenues
fell
54%
to
$1.6
million.
Net
loss
applicable
to
Com.
rose
23%
to
$11.4
million.
Revenues
reflect
a
lower
level
of
product
development
activities.
Higher
loss
reflects
an
increase
in
personnel,
clinical,
marketing,
and
amortization
of
goodwill
and
deferred
stock-based
compensation
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Jane Shaw, Ph.D., 62 Chairman,
CEO | $290K | -- | Deborah Karlson, 48 CFO | 180K | $1.0M | Carol Gamble, 48 VP,
Gen. Counsel | 200K | -- | Michael Klimowicz, 50 VP,
Product Devel. | 204K | 1.0M | John Power, 41 VP,
European Operations | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|